Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
04:15pm, Tuesday, 07'th May 2024
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
09:11am, Thursday, 02'nd May 2024
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength
Why Is CytomX (CTMX) Stock Up 180% Today?
11:43am, Wednesday, 01'st May 2024
CytomX (NASDAQ: CTMX ) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report. The oncology-focused biopharmaceutical company told
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
08:00am, Wednesday, 01'st May 2024
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
06:33pm, Thursday, 25'th Apr 2024
CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-90
GSK Gears Up for Q1 Earnings: Here's What to Expect
02:21pm, Tuesday, 23'rd Apr 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the fir
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date -
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
08:00am, Thursday, 21'st Mar 2024
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the app
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
08:00am, Monday, 18'th Mar 2024
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -
Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today?
09:12am, Tuesday, 12'th Mar 2024
CytomX Therapeutics (NASDAQ: CTMX ) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report. The CytomX Therapeutics
CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript
06:39pm, Monday, 11'th Mar 2024
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chie
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
06:21pm, Monday, 11'th Mar 2024
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.42 per share a year ago.
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
04:10pm, Monday, 11'th Mar 2024
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 -
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
08:00am, Monday, 04'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it
